TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Treatment Success
Endpoint domain: Adverse events/effects
Primary endpoint: Implantation rate by biological test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Implantation rate by ultrasound test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: H pylori eradication
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Time between targets (lag time)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in percent correct in speech perception
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCinf of ethinyloestradiol (EE) and levonorgestrel (LN)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Smartphone Addiction Scale-Short Form
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Positive clinical performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in cerebral blood flow velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clinical tolerance of chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in cranial arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Plasma oxalate rate (oxalemia)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Fibromyalgia Impact Questionnaire (FIQR)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: skin condition following treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Sensitivity of CL detect Rapid Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of CL detect Rapid Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Balance-Postural Stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Technical success of EUS-guided RFA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Side effects and adverse events of EUS-guided RFA
Endpoint domain: Adverse events/effects
Primary endpoint: Area under the concentration-time curve from time zero to time of last quantifiable concentration (AUC0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Implant stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stability of Acetabular and femoral components
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Maximum Tolerated dose of RC98
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients identified as having atrial fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of patients identified as not having atrial fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percent of Patients With Minimal Residual Disease (MRD) Status Changing to Negative
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peak aerobic capacity (VO2peak)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Differences in BLVRA expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acetabular Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: International Hip Dysplasia Institute Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in clinical symptoms of Allergen Rhinitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients Who Achieved Clinical Symptom Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of tendon stress in pascals at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of tendon vascularity index as percentage at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brief Pain Inventory (BPI) Average Score at Baseline
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Brief Pain Inventory (BPI) Average Score at Day 28
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Number of Participants With Treatment-Emergent Serious AEs (TESAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With AEs of Special Interest (AESIs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With New Onset Chronic Disease (NOCDs)
Endpoint domain: Adverse events/effects
Primary endpoint: Femoral anteversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum B12 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Methylmalonic acid concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: homocystein concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: holotranscobalamin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: McGill Quality of Life Questionnaire -Expanded Total Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quality of Life in Life-Threatening Illness- Family Total Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence, severity, and dose-relationship of adverse effects
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in serum ANGPTL3 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Acuity - Subjective Assessment at Age 4.5 Years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Acuity - Subjective Assessment at Age 10 Years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perception of well being
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Area under the curve from the time of dosing to steady state (AUC(0-τ)ss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Any Treatment-emergent Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Grades 3 and 4 Treatment-emergent Adverse Events (AEs) of Special Interest
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Drug-Related Treatment-emergent AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Pulmonary pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Level of parental adjustment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: change in number of minutes of moderate to strenuous physical activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Net Protein Synthesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Simple Endoscopic Score for Crohn's Disease (SES-CD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Hemoglobin consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of a treatment-emergent antibody with confirmed specificity to S 303 treated red blood cells (RBC)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of off-protocol platelet transfusions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Total number of platelet transfusions/group
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Adherence to tranexamic acid use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: ELISA test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in microbial composition in feces
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Participants With Gastrointestinal Failure Score Equal 0
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Occurrence of clinical significant retinopathy progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Prevalence of cardiovascular sequelae
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prevalence of psychological sequelae
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: % of dressings achieving a 7 day wear time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to achieve a 7 day wear time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Condition of the peri-ulcer skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Retention of randomized participants
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mucosal Recession Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients With Cure, Improved, Failure or Death
Endpoint domain: Mortality/survival
Primary endpoint: Mean and maximum blood pressure difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Imaging characteristics of 64CU-ECL1i
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and efficacy of Naloxegol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immune response to varicella zoster virus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Phase 2 anthocyanin conjugates in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success Rate of Placement of a Thoracic Epidural
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Sperm Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Percentage of Participants With Clinical Response-100 or Clinical Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Malignant glioma uptake of 68Ga-DOTATOC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in intrathoracic impedance values (ohms)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in OptiVol Index Values (ohm-days)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Postoperative pancreatic fistula (POPF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: All cause 30-day mortality
Endpoint domain: Mortality/survival
Primary endpoint: First Cycle Dose Limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients With All-Causality Treatment-Emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Serum cortisol sample
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: decrease in peripheral systolic blood pressure at night
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Menstrual bleeding questionnaire score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Atrophic Acne Scar Count Per Half-face
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Accuracy of tests in identifying bacteria or fungi
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Time from RECIST progression to secondary disease progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Nasal airflow/pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective Nasal Obstruction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of acute toxicity leading to treatment interruption
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of complete endoscopic response at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival without locoregional relapse at 2 years
Endpoint domain: Mortality/survival
Primary endpoint: Dioptric power of subject
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Corneal topography parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence of Peritonsillar Abscess
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of facial nerve injury
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline hamstring strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Medical complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: absolute reinforcing value of food
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reliability of the KCPS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daily average activity-related acceleration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HAM-D 21 score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Subjects Requiring Dose Modifications
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in faecal bacteria population
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Urinary THC-COOH:creatinine below 50ng/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of days abstinent from cannabis
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: DSM-5 criteria for moderate cannabis dependence
Endpoint domain: Adverse events/effects
Primary endpoint: Toffee Mask Usability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Toffee Mask Comfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Toffee Mask Treatment Performance - Subjective
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trial Mask Acceptability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage reduction in plaque calcification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage reduction in carotid stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With a Dose-Limiting Toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in Multiple Sclerosis Functional Composite (MSFC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CMV viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the amount of opioid prescribed
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Shoulder/Arm Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Beta-cell function index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Manual Muscle Testing 8 (MMT8)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Clinical Global Impressions Scale - Improvement - Social
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Repetitive Behavior Scale - Revised
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic Analysis of Nonverbal Accuracy, Paralanguage Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pulmonary artery pressure during exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: change in Self-Stigma
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: change in perceived family burden
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: Change of maximum bronchial cuff pressure (BCP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Functional Magnetic Resonance Imaging (fMRI) Correlation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Difference in effective ratio of medical device
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: First Hospitalization for Worsening Heart Failure or Death
Endpoint domain: Mortality/survival
Primary endpoint: Implant Attempt Without Complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: cardiac morphology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: epicardial adipose tissue volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improved Symptom Ratings
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Postmastectomy pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alanine Transaminase (ALT) Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients Meeting ACR Pediatric 30 Criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Rate of hepatic de novo lipogenesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Patients with Day 14 Cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-Time Curve (AUC0-28days) of Buprenorphine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Buprenorphine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of surface landmarks for prediction of CVC depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Accuracy of C-length for prediction of CVC depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of participants with HFNC success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with CPAP/NPPV success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in levels of circulating miRNAs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation between the level of the circulating miRNAs and the maximal diameter of the aneurysm sac
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiovascular Death (Days Alive)
Endpoint domain: Mortality/survival
Primary endpoint: Cardiovascular Hospitalization (Days Out of Hospital)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Heart Failure Symptoms (Symptom Score)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Achievement of two consecutive greater than or equal to 30% decreases from baseline iPTH levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Incidence of clinically meaningful hypercalcemia and elevated Ca x P
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in symptoms of major depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of all-cause mortality
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Unplanned hospital admission
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Percentage of Emergency visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Percentage of Institutionalization
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Duration of class IV neutrophilic granulocytopenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Aix@75
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: AEs or SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Disease progression in participants with MPS IIIB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: progression rate of CIN+ or VaIN+
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Participants With Rabies Virus Neutralizing Antibody Titers >= 0.5 IU/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: times of infections
Endpoint domain: Adverse events/effects
Primary endpoint: Survival after pacemaker implantation
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants Achieving Treatment Success
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life